You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

~ Buy the AMVUTTRA (vutrisiran sodium) Drug Profile, 2024 PDF Report in the Report Store ~

AMVUTTRA Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Amvuttra patents expire, and what generic alternatives are available?

Amvuttra is a drug marketed by Alnylam Pharms Inc and is included in one NDA. There are thirteen patents protecting this drug.

This drug has two hundred and thirty-two patent family members in forty-six countries.

The generic ingredient in AMVUTTRA is vutrisiran sodium. One supplier is listed for this compound. Additional details are available on the vutrisiran sodium profile page.

DrugPatentWatch® Generic Entry Outlook for Amvuttra

Amvuttra will be eligible for patent challenges on June 13, 2026. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be July 28, 2036. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Subscribe

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for AMVUTTRA?
  • What are the global sales for AMVUTTRA?
  • What is Average Wholesale Price for AMVUTTRA?
Summary for AMVUTTRA
International Patents:232
US Patents:13
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Drug Prices: Drug price information for AMVUTTRA
What excipients (inactive ingredients) are in AMVUTTRA?AMVUTTRA excipients list
DailyMed Link:AMVUTTRA at DailyMed
Drug patent expirations by year for AMVUTTRA
Drug Prices for AMVUTTRA

See drug prices for AMVUTTRA

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for AMVUTTRA
Generic Entry Date for AMVUTTRA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION;SUBCUTANEOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for AMVUTTRA

AMVUTTRA is protected by thirteen US patents and two FDA Regulatory Exclusivities.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of AMVUTTRA is ⤷  Subscribe.

This potential generic entry date is based on patent 10,208,307.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Alnylam Pharms Inc AMVUTTRA vutrisiran sodium SOLUTION;SUBCUTANEOUS 215515-001 Jun 13, 2022 RX Yes Yes 11,401,517 ⤷  Subscribe Y Y ⤷  Subscribe
Alnylam Pharms Inc AMVUTTRA vutrisiran sodium SOLUTION;SUBCUTANEOUS 215515-001 Jun 13, 2022 RX Yes Yes 10,131,907 ⤷  Subscribe Y Y ⤷  Subscribe
Alnylam Pharms Inc AMVUTTRA vutrisiran sodium SOLUTION;SUBCUTANEOUS 215515-001 Jun 13, 2022 RX Yes Yes 10,683,501 ⤷  Subscribe Y Y ⤷  Subscribe
Alnylam Pharms Inc AMVUTTRA vutrisiran sodium SOLUTION;SUBCUTANEOUS 215515-001 Jun 13, 2022 RX Yes Yes 12,049,628 ⤷  Subscribe Y Y ⤷  Subscribe
Alnylam Pharms Inc AMVUTTRA vutrisiran sodium SOLUTION;SUBCUTANEOUS 215515-001 Jun 13, 2022 RX Yes Yes 8,106,022 ⤷  Subscribe Y Y ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for AMVUTTRA

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Alnylam Netherlands B.V. Amvuttra vutrisiran EMEA/H/C/005852
Treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy.
Authorised no no yes 2022-09-15
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for AMVUTTRA

When does loss-of-exclusivity occur for AMVUTTRA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Patent: 5543
Estimated Expiration: ⤷  Subscribe

Brazil

Patent: 2018000542
Estimated Expiration: ⤷  Subscribe

Canada

Patent: 94285
Estimated Expiration: ⤷  Subscribe

Chile

Patent: 18000198
Estimated Expiration: ⤷  Subscribe

China

Patent: 8138182
Estimated Expiration: ⤷  Subscribe

Patent: 6064515
Estimated Expiration: ⤷  Subscribe

Croatia

Patent: 0202082
Estimated Expiration: ⤷  Subscribe

Cyprus

Patent: 24545
Estimated Expiration: ⤷  Subscribe

Denmark

Patent: 29002
Estimated Expiration: ⤷  Subscribe

Eurasian Patent Organization

Patent: 1890394
Estimated Expiration: ⤷  Subscribe

European Patent Office

Patent: 29002
Estimated Expiration: ⤷  Subscribe

Finland

Patent: 0230006
Estimated Expiration: ⤷  Subscribe

France

Patent: C1008
Estimated Expiration: ⤷  Subscribe

Hong Kong

Patent: 56494
Estimated Expiration: ⤷  Subscribe

Patent: 56683
Estimated Expiration: ⤷  Subscribe

Hungary

Patent: 51998
Estimated Expiration: ⤷  Subscribe

Patent: 300007
Estimated Expiration: ⤷  Subscribe

Israel

Patent: 6614
Estimated Expiration: ⤷  Subscribe

Patent: 6476
Estimated Expiration: ⤷  Subscribe

Patent: 3082
Estimated Expiration: ⤷  Subscribe

Japan

Patent: 96703
Estimated Expiration: ⤷  Subscribe

Patent: 17559
Estimated Expiration: ⤷  Subscribe

Patent: 18523655
Estimated Expiration: ⤷  Subscribe

Patent: 21167313
Estimated Expiration: ⤷  Subscribe

Patent: 24028749
Estimated Expiration: ⤷  Subscribe

Lithuania

Patent: 2023505
Estimated Expiration: ⤷  Subscribe

Patent: 29002
Estimated Expiration: ⤷  Subscribe

Malaysia

Patent: 5720
Estimated Expiration: ⤷  Subscribe

Mexico

Patent: 18000981
Estimated Expiration: ⤷  Subscribe

Patent: 23012080
Estimated Expiration: ⤷  Subscribe

Morocco

Patent: 335
Estimated Expiration: ⤷  Subscribe

Netherlands

Patent: 1216
Estimated Expiration: ⤷  Subscribe

Norway

Patent: 23007
Estimated Expiration: ⤷  Subscribe

Poland

Patent: 29002
Estimated Expiration: ⤷  Subscribe

Portugal

Patent: 29002
Estimated Expiration: ⤷  Subscribe

Serbia

Patent: 297
Estimated Expiration: ⤷  Subscribe

Singapore

Patent: 201912341S
Estimated Expiration: ⤷  Subscribe

Slovenia

Patent: 29002
Estimated Expiration: ⤷  Subscribe

South Africa

Patent: 1800571
Estimated Expiration: ⤷  Subscribe

Patent: 1902447
Estimated Expiration: ⤷  Subscribe

South Korea

Patent: 2667020
Estimated Expiration: ⤷  Subscribe

Patent: 180028537
Estimated Expiration: ⤷  Subscribe

Patent: 240074895
Estimated Expiration: ⤷  Subscribe

Spain

Patent: 42300
Estimated Expiration: ⤷  Subscribe

Taiwan

Patent: 27963
Estimated Expiration: ⤷  Subscribe

Patent: 07302
Estimated Expiration: ⤷  Subscribe

Patent: 1718855
Estimated Expiration: ⤷  Subscribe

Patent: 2130810
Estimated Expiration: ⤷  Subscribe

Patent: 2344688
Estimated Expiration: ⤷  Subscribe

Ukraine

Patent: 6276
Estimated Expiration: ⤷  Subscribe

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering AMVUTTRA around the world.

Country Patent Number Title Estimated Expiration
China 104080794 RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases ⤷  Subscribe
Japan 2024020209 修飾二本鎖RNA剤 ⤷  Subscribe
Cyprus 1123693 ⤷  Subscribe
World Intellectual Property Organization (WIPO) 2008131419 ⤷  Subscribe
New Zealand 624471 Modified rnai agents ⤷  Subscribe
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for AMVUTTRA

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
3329002 CA 2023 00008 Denmark ⤷  Subscribe PRODUCT NAME: VUTRISIRAN; REG. NO/DATE: EU/1/22/1681 20220916
3329002 CR 2023 00008 Denmark ⤷  Subscribe PRODUCT NAME: VUTRISIRAN; REG. NO/DATE: EU/1/22/1681 20220916
3329002 PA2023505,C3329002 Lithuania ⤷  Subscribe PRODUCT NAME: VUTRISIRANAS; REGISTRATION NO/DATE: EU/1/22/1681 20220915
3329002 PA2023505 Lithuania ⤷  Subscribe PRODUCT NAME: VUTRISIRANAS; REGISTRATION NO/DATE: EU/1/22/1681 20220915
3329002 7/2023 Austria ⤷  Subscribe PRODUCT NAME: VUTRISIRAN; REGISTRATION NO/DATE: EU/1/22/1681 (MITTEILUNG) 20220916
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

AMVUTTRA Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for AMVUTTRA

Introduction to AMVUTTRA

AMVUTTRA, developed by Alnylam Pharmaceuticals, is a groundbreaking RNA interference (RNAi) therapeutic designed to treat transthyretin-mediated amyloidosis (ATTR), including both polyneuropathy and cardiomyopathy (ATTR-CM). Here, we delve into the market dynamics and financial trajectory of this promising drug.

Current Market Performance

AMVUTTRA has shown impressive growth since its launch. In the third quarter of 2024, AMVUTTRA generated $259 million in revenues, marking a 74% year-over-year growth. This strong performance is part of Alnylam's overall TTR franchise success, which drove the company's global net product revenues to $420 million, a 34% increase from the previous year[2].

Financial Outlook

The financial outlook for AMVUTTRA is highly optimistic. Analysts project peak sales of approximately $3.7 billion in the U.S. and $1.8 billion in the European Union for the combined polyneuropathy and ATTR-CM indications. Some projections even suggest peak sales could reach $5 billion to $6 billion, although competition from Pfizer's Vyndamax is expected to continue[1][3].

Revenue Growth Projections

Alnylam's financial trajectory indicates significant revenue growth driven by AMVUTTRA. The company's revenues are expected to grow from $1,828 million in 2023 to $2,908 million in 2025. This growth is largely attributed to the strong commercial performance of AMVUTTRA and the potential expansion of its patient population with the approval for ATTR-CM[3][5].

Cash Position and Financial Health

As of September 30, 2024, Alnylam's cash position stood at $2.78 billion, up from $2.44 billion in December 2023. This strong cash position, combined with a healthy current ratio of 2.75 and an impressive gross profit margin of 85.37%, underscores the company's financial stability and ability to invest in further research and development[2][5].

Competitive Landscape

AMVUTTRA operates in a competitive market, particularly against Pfizer's Vyndamax. However, AMVUTTRA's strong clinical profile, including a 36% reduction in all-cause mortality, sets it apart. The drug's quarterly dosing regimen and novel mechanism of action as an RNAi therapeutic are additional advantages that could lead to guideline updates recommending AMVUTTRA as the preferred initial treatment for ATTR-CM[3].

Challenges and Risks

Despite the promising outlook, Alnylam faces several challenges that could impact AMVUTTRA's commercial success. These include reimbursement hurdles, potential manufacturing and supply chain issues, regulatory delays, and the challenge of convincing physicians to switch from established therapies like tafamidis[3].

Pipeline and Future Growth Opportunities

Beyond AMVUTTRA, Alnylam's pipeline includes several promising candidates that could further drive growth. These include next-generation therapies that could be dosed annually, advanced pipeline programs such as Zilebesiran and ALN-APP, and potential extrahepatic programs. The success of HELIOS-B has heightened expectations for these pipeline assets[3].

Impact on Alnylam's Financial Future

The successful commercialization of AMVUTTRA is crucial for Alnylam's financial future. While the company is currently operating at a loss with negative EPS projected through 2024, the positive HELIOS-B results have reinforced the goal of achieving non-GAAP operating profitability by the end of 2025. The strong uptake of AMVUTTRA and its potential to become a first-line therapy for ATTR-CM are key factors in this financial strategy[3][5].

Clinical and Commercial Success Factors

AMVUTTRA's clinical success, particularly its mortality benefit, is a significant driver of its adoption. The drug's ability to reduce all-cause mortality by 36% provides clear clinical value and differentiates it from existing therapies. The quarterly dosing regimen and potential for combination therapy with tafamidis further enhance its market appeal[3].

Market Expansion and Patient Population

The approval for ATTR-CM could expand AMVUTTRA's patient population significantly. With noninvasive diagnosis techniques becoming more available, the patient population for AMVUTTRA could increase 10-fold, from between 30,000 to 60,000 for polyneuropathy to a much larger population for ATTR-CM[1].

Regulatory Approvals and Submissions

Alnylam has submitted regulatory applications in the U.S. and EU for AMVUTTRA for the treatment of ATTR-CM. The successful outcome of these submissions is critical for the drug's commercial expansion and the company's financial growth[2].

Key Takeaways

  • AMVUTTRA has shown strong revenue growth, generating $259 million in Q3 2024.
  • Projected peak sales range from $3.7 billion to $6 billion.
  • Alnylam's financial trajectory indicates significant revenue growth to $2.908 billion by 2025.
  • The company faces challenges such as reimbursement hurdles and market penetration.
  • AMVUTTRA's clinical profile, including a 36% reduction in all-cause mortality, is a key driver of its adoption.
  • Successful commercialization of AMVUTTRA is crucial for Alnylam's financial future.

FAQs

What is AMVUTTRA and how does it work?

AMVUTTRA is an RNA interference (RNAi) therapeutic developed by Alnylam Pharmaceuticals to treat transthyretin-mediated amyloidosis (ATTR), including polyneuropathy and cardiomyopathy (ATTR-CM). It works by silencing the gene responsible for producing the transthyretin protein, thereby reducing the formation of amyloid deposits.

How has AMVUTTRA performed financially since its launch?

AMVUTTRA has shown significant financial growth, with revenues of $259 million in the third quarter of 2024, representing a 74% year-over-year increase.

What are the projected peak sales for AMVUTTRA?

Analysts project peak sales of approximately $3.7 billion in the U.S. and $1.8 billion in the European Union for the combined polyneuropathy and ATTR-CM indications, with some projections as high as $5 billion to $6 billion.

What challenges does Alnylam face in achieving profitability with AMVUTTRA?

Alnylam faces challenges such as reimbursement hurdles, manufacturing and supply chain issues, regulatory delays, and market penetration challenges in convincing physicians to switch from established therapies.

How does AMVUTTRA differentiate itself from other treatments for ATTR-CM?

AMVUTTRA's strong clinical profile, including a 36% reduction in all-cause mortality, its quarterly dosing regimen, and its novel mechanism of action as an RNAi therapeutic differentiate it from other treatments like tafamidis.

What is the impact of AMVUTTRA on Alnylam's overall financial health?

The successful commercialization of AMVUTTRA is crucial for Alnylam's financial future, aiming to achieve non-GAAP operating profitability by the end of 2025, despite current operating losses.

Cited Sources:

  1. Biospace: "Alnylam Could Challenge Pfizer in ATTR-CM But Experts Want Full Data"[1]
  2. Stocktitan: "Alnylam Pharmaceuticals Reports Third Quarter 2024 Financial Results"[2]
  3. Investing.com: "Alnylam's SWOT analysis: strong helios-b data bolsters amvuttra stock outlook"[3]
  4. Fiercepharma: "Amvuttra makes inroads in ATTR as Alnylam scraps heart disease trial"[4]
  5. Investing.com: "Alnylam's SWOT analysis: strong helios-b data bolsters amvuttra stock outlook"[5]

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.